Holy Grail, page-19

Since completing the BIT225-009 Phase 2 HIV-1 clinical trial and releasing positive results in late 2018, Biotron has continued to characterise the unique mechanism of action of its lead antiviral drug, BIT225. This has involved detailed post-trial analyses of trial samples. These analyses now provide key information on how BIT225 induces the significant beneficial immunological changes observed in the completed Phase 2 clinical trial and form the basis of the paper to be presented at CROI.

With this happening overnight ... being out of this stock is a big risk.